Strategic Mergers Clinipace Worldwide has a history of strategic mergers (Choice Pharma in 2014 and Accovion in 2015) which expanded capabilities and geographic footprint. This presents opportunities to upsell integrated, end-to-end CRO services across broader therapeutic areas and global regions.

Digital CRO Advantage Position Clinipace as a digitally powered CRO (dCRO) with TEMPO platform to streamline regulatory, clinical, and post-approval research. Target sponsors seeking faster trial delivery, reduced cycle times, and higher data integrity through a proprietary eClinical stack.

Therapeutic Breadth Extensive therapeutic expertise across cardiovascular, CNS, dermatology, oncology, immunology, infectious diseases, and vaccines enables cross-therapy client engagements. Leverage breadth to pursue multi-therapy programs, companion studies, and regulatory strategies for complex portfolios.

Growth Signals Recent leadership changes and strategic financing activity signal growth momentum and potential capacity expansion. Engage early with opportunities in expanding global offices, increased project throughput, and upgraded services aligned to sponsor forecasts.

Scale and Collaboration Historically supported over 3,000 clinical studies and 300+ regulatory projects, with a mid-market size (501–1000 employees) positioning as a scalable partner for mid-to-large pharma, biotech, and medical device firms seeking personalized attention with global reach.